

AMENDMENTS TO THE CLAIMS

Please incorporate the following amendments to the subject application.

In the Claims:

1. – 9. (Canceled)

10. **(Currently Amended)** A method for the production of a viral particle, comprising:
culturing a cell in the presence of a **donor** virus or a sample suspected of containing a virus, said culturing being under conditions suitable for efficient viral replication, said cell having a targeted deletion in at least one of a protein kinase RNA-dependent (PKR) gene, a 2'-5'-linked oligoadenylate (2-5A) synthetase gene, or an Mx gene, wherein said cell has increased permissiveness to viral replication due to said targeted deletion; and
harvesting the viral particles produced.

11. **(Previously Presented)** The method of claim 10, further comprising inactivating the viral particles produced for the production of a viral vaccine.

12. **(Previously Presented)** The method of claim 11, wherein said method further comprises preparing a viral vaccine from said harvested viral particles.

13. **(Previously Presented)** The method of claim 10, wherein said cell is deficient in interferon-mediated antiviral responses relative to a cell without the targeted deletion.

14. **(Previously Presented)** The method of claim 10, further comprising determining viral titer prior to said harvesting.

15. **(Previously Presented)** The method of claim 14, wherein the viral vaccine is suitable for human administration.

16. **(Previously Presented)** The method of claim 14, further comprising formulating the viral particles produced thereby with a pharmaceutically acceptable carrier.

17. **(Currently Amended)** The method of claim 10, wherein said ~~deficient~~ cell is a human cell.

18. **(Currently Amended)** The method of claim 10, wherein said ~~deficient~~ cell is chosen from MRC-5, WI-38, Chang liver, U937, Vero, MRC-9, IMR-90, IMR-91, Lederle 130, MDCK, H9, CEM, or CD4-expressing HUT78.

19. **(Currently Amended)** The method of claim 18, wherein said ~~deficient~~ cell is a MRC-5 or WI-38 or Vero cell.

20. **(Currently Amended)** The method of claim 10, wherein said ~~deficient~~ cell is a U937 cell.

21. **(Previously Presented)** The method of claim 10, wherein said donor virus is an attenuated virus.

22. **(Previously Presented)** The method of claim 10, wherein said donor virus is a recombinant virus.

23. **(Previously Presented)** The method of claim 10, wherein said donor virus is a human influenza virus.

24. **(Previously Presented)** The method of claim 10, wherein said donor virus is a non-human virus.

25. **(Currently Amended)** The method of claim 10, wherein said ~~deficient~~ cell is deficient in both PKR and 2-5A synthetase.

26. **(Currently Amended)** A method for the production of a viral particle, comprising:

culturing a cell in the presence of a **donor** virus or a sample suspected of containing a virus, said culturing being under conditions suitable for viral replication, said cell having a targeted deletion in a protein kinase RNA-dependent (PKR) gene, wherein the cell has increased permissiveness to viral replication as a result of said targeted deletion; and
harvesting the viral particles produced.

27. **(Previously Presented)** The method of claim 26, further comprising inactivating the viral particles produced.

28. **(Previously Presented)** The method of claim 27, wherein said method further comprises preparing a viral vaccine from said harvested viral particles.

29. **(Previously Presented)** The method of claim 26, wherein the cell has a further targeted deletion in a 2-5A synthetase gene.

30. **(Previously Presented)** The method of claim 26, wherein the cell has a further targeted deletion in a Mx gene.

31. **(Previously Presented)** The method of claim 26, further comprising determining viral titer prior to said harvesting step.

32. **(Currently Amended)** The method of ~~claim 26~~ **claim 28**, wherein the viral vaccine is suitable for human administration.

33. **(Previously Presented)** The method of claim 26, further comprising formulating the viral particles produced with a pharmaceutically acceptable carrier.

34. **(Currently Amended)** The method of claim 26, wherein said ~~deficient~~ cell is a human cell.

35. **(Currently Amended)** The method of claim 26, wherein said ~~deficient~~ cell is chosen from MRC-5, WI-38, Chang liver, U937, Vero, MRC-9, IMR-90, IMR-91, Lederle 130, MDCK, H9, CEM, or CD4-expressing HUT78.

36. **(Currently Amended)** The method of claim 26, wherein said ~~deficient~~ cell is a MRC-5 or WI-38 or Vero cell.

37. **(Currently Amended)** The method of claim 26, wherein said ~~deficient~~ cell is a U937 cell.

38. **(Previously Presented)** The method of claim 26, wherein said donor virus is an attenuated virus.

39. **(Previously Presented)** The method of claim 26, wherein said donor virus is a recombinant virus.

40. **(Previously Presented)** The method of claim 26, wherein said donor virus is a human influenza virus.

41. **(Previously Presented)** The method of claim 26, wherein said donor virus is a non-human virus.